Gapping up
In reaction to strong earnings/guidance:
- RH +20.9%, PLAY +13.8%, LE +10.6%, KMG +5.9%, URBN +3.8%, (discloses that thus far during the Q2, comparable Retail segment net sales are mid teens positive)
M&A news:
- QCP +1.2% (announces receipt of acquisition proposal that could reasonably be expected to lead to a 'Superior Offer')
- SGH +1.1% (acquires Penguin Computing for up to $85 million, which includes up to $25 million of performance-based payments)
Other news:
- GLMD +221.4% (announces top-line, 52-week results from the global Phase 2b ARREST study, says data strongly support advancement of Aramchol 600mg to Phase 3)
- BLDP +12.2% (signs 3.5-Year extension to long-term program for fuel cell passenger cars with AUDI AG)
- PSTI +8.6% (positive top-line results from its multinational Phase II clinical study of PLX-PAD cells in the treatment of Intermittent Claudication)
- TNDM +4.2% (Deerfield Mgmt discloses 5.54% passive stake)
- SAGE +4% (announces expedited development plan for SAGE-217 following a Breakthrough Therapy meeting with the FDA)
- PFNX +2.6% (Pfenex and Alvogen enter into agreement granting Alvogen exclusive rights to commercialize Pfenex's lead drug candidate, PF708)
- I +1.5% (prices concurrent offerings of common shares and convertible notes)
Analyst comments:
- WTW +3% (initiated with a Overweight at JP Morgan)
- ENBL +1% (upgraded to Equal Weight from Underweight at Barclays)
- ALB +0.9% (upgraded to Buy from Hold at Vertical Research)
![]()